title: Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity.
abstract: The emergence of a new agent of cholera, Vibrio cholerae O139, has prompted a reevaluation of the vibriocidal antibody assay. This assay, primarily directed to lipopolysaccharide, is an important correlate of O1 immunity. V. cholerae O139 strains are encapsulated, rendering them relatively resistant to killing by serum. Recent reports suggest that there is strain-to-strain variability in the sensitivity of the vibriocidal assay to fully encapsulated O139 strains. We have assessed a modified vibriocidal assay for fully encapsulated O139 strain AI-1837 and its unencapsulated mutant 2L in sera from 53 volunteers given wild-type AI-1837 or its attenuated derivative CVD 112 and from 48 controls challenged with V. cholerae O1 or strains of the family Enterobacteriaceae. Vibriocidal responses to the AI-1837 and 2L strains were seen in 67 and 89% of volunteers, respectively, following a single exposure to the wild-type strain. However, >50% of all controls had low-level vibriocidal responses to both strains. These nonspecific responses were transient and of the immunoglobulin G isotype. No binding activity against purified O139 lipopolysaccharide (LPS) by immunoblotting was seen in control sera. In contrast, vibriocidal assay and strain 2L LPS responses by immunoblotting were detectable in 91% of tested volunteers following a single exposure to O139. The presence of vibriocidal antibody to AI-1837 or 2L was not associated with protection in rechallenge studies with O139 strain AI-1837. The vibriocidal assay with unencapsulated strain 2L may be used to detect exposure to O139 strain AI-1837 in controlled research trials. However, its lack of specificity does not make it useful for determining exposure to V. cholerae O139 in the field.
authors.affiliation: Center for Vaccine Development, University of Maryland School of Medicine, and Veterans Affairs Medical Center of Baltimore, 21201, USA.
authors.forename: G A
authors.initials: GA
authors.lastname: Losonsky
authors.forename: Y
authors.initials: Y
authors.lastname: Lim
authors.forename: P
authors.initials: P
authors.lastname: Motamedi
authors.forename: L E
authors.initials: LE
authors.lastname: Comstock
authors.forename: J A
authors.initials: JA
authors.lastname: Johnson
authors.forename: J G
authors.initials: JG
authors.lastname: Morris
authors.forename: C O
authors.initials: CO
authors.lastname: Tacket
authors.forename: J B
authors.initials: JB
authors.lastname: Kaper
authors.forename: M M
authors.initials: MM
authors.lastname: Levine
mesh_terms: D000907:Antibodies, Bacterial / Q000096:biosynthesis* / Q000097:blood; D000918:Antibody Specificity; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines / Q000494:pharmacology*; D002771:Cholera / Q000276:immunology / Q000517:prevention & control; D006801:Humans; D015151:Immunoblotting; D008070:Lipopolysaccharides / Q000276:immunology; D009154:Mutation; D012703:Serotyping; D013045:Species Specificity; D014734:Vibrio cholerae / Q000145:classification / Q000235:genetics / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines; D008070:Lipopolysaccharides